Andrew Tutt, PhD, MBChB, on Clinical Implications of Treating Metastatic Breast Cancer With Olaparib

Posted: Wednesday, July 14, 2021

Andrew Tutt, PhD, MBChB, of the Institute of Cancer Research, London, discusses key evidence from the OlympiA trial for clinicians treating women with BRCA-mutated and high-risk HER2-negative early breast cancer and how this study may alter the treatment landscape.